| Literature DB >> 32268092 |
Nathan A Dahl1, Etienne Danis2, Ilango Balakrishnan2, Dong Wang2, Angela Pierce2, Faye M Walker2, Ahmed Gilani3, Natalie J Serkova4, Krishna Madhavan2, Susan Fosmire2, Adam L Green5, Nicholas K Foreman6, Sujatha Venkataraman2, Rajeev Vibhakar7.
Abstract
Histone 3 gene mutations are the eponymous drivers in diffuse midline gliomas (DMGs), aggressive pediatric brain cancers for which no curative therapy currently exists. These recurrent oncohistones induce a global loss of repressive H3K27me3 residues and broad epigenetic dysregulation. In order to identify therapeutically targetable dependencies within this disease context, we performed an RNAi screen targeting epigenetic/chromatin-associated genes in patient-derived DMG cultures. This identified AFF4, the scaffold protein of the super elongation complex (SEC), as a molecular dependency in DMG. Interrogation of SEC function demonstrates a key role for maintaining clonogenic potential while promoting self-renewal of tumor stem cells. Small-molecule inhibition of SEC using clinically relevant CDK9 inhibitors restores regulatory RNA polymerase II pausing, promotes cellular differentiation, and leads to potent anti-tumor effect both in vitro and in patient-derived xenograft models. These studies present a rationale for further exploration of SEC inhibition as a promising therapeutic approach to this intractable disease.Entities:
Keywords: AFF4; AZD4573; CDK9; DIPG; DMG; SEC; atuveciclib; diffuse intrinsic pontine glioma; diffuse midline glioma; super elongation complex
Mesh:
Substances:
Year: 2020 PMID: 32268092 DOI: 10.1016/j.celrep.2020.03.049
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423